Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of DKK 97.67 billion. The enterprise value is 80.20 billion.
Market Cap | 97.67B |
Enterprise Value | 80.20B |
Important Dates
The last earnings date was Thursday, August 7, 2025.
Earnings Date | Aug 7, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Genmab has 61.51 million shares outstanding. The number of shares has decreased by -3.37% in one year.
Current Share Class | 61.51M |
Shares Outstanding | 61.51M |
Shares Change (YoY) | -3.37% |
Shares Change (QoQ) | -3.04% |
Owned by Insiders (%) | 1.12% |
Owned by Institutions (%) | 51.05% |
Float | 60.81M |
Valuation Ratios
The trailing PE ratio is 11.56 and the forward PE ratio is 14.38. Genmab's PEG ratio is 2.53.
PE Ratio | 11.56 |
Forward PE | 14.38 |
PS Ratio | 4.22 |
PB Ratio | 2.90 |
P/TBV Ratio | 4.81 |
P/FCF Ratio | 14.09 |
P/OCF Ratio | 13.56 |
PEG Ratio | 2.53 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.39, with an EV/FCF ratio of 11.57.
EV / Earnings | 9.21 |
EV / Sales | 3.46 |
EV / EBITDA | 9.39 |
EV / EBIT | 9.91 |
EV / FCF | 11.57 |
Financial Position
The company has a current ratio of 6.22, with a Debt / Equity ratio of 0.03.
Current Ratio | 6.22 |
Quick Ratio | 6.20 |
Debt / Equity | 0.03 |
Debt / EBITDA | 0.11 |
Debt / FCF | 0.14 |
Interest Coverage | 49.22 |
Financial Efficiency
Return on equity (ROE) is 28.12% and return on invested capital (ROIC) is 15.86%.
Return on Equity (ROE) | 28.12% |
Return on Assets (ROA) | 13.26% |
Return on Invested Capital (ROIC) | 15.86% |
Return on Capital Employed (ROCE) | 21.84% |
Revenue Per Employee | 8.78M |
Profits Per Employee | 3.30M |
Employee Count | 2,682 |
Asset Turnover | 0.61 |
Inventory Turnover | 21.91 |
Taxes
In the past 12 months, Genmab has paid 1.16 billion in taxes.
Income Tax | 1.16B |
Effective Tax Rate | 11.77% |
Stock Price Statistics
The stock price has decreased by -14.94% in the last 52 weeks. The beta is 0.80, so Genmab's price volatility has been lower than the market average.
Beta (5Y) | 0.80 |
52-Week Price Change | -14.94% |
50-Day Moving Average | 1,425.07 |
200-Day Moving Average | 1,439.33 |
Relative Strength Index (RSI) | 65.17 |
Average Volume (20 Days) | 140,488 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genmab had revenue of DKK 23.16 billion and earned 8.71 billion in profits. Earnings per share was 137.33.
Revenue | 23.16B |
Gross Profit | 21.90B |
Operating Income | 8.10B |
Pretax Income | 9.87B |
Net Income | 8.71B |
EBITDA | 8.43B |
EBIT | 8.10B |
Earnings Per Share (EPS) | 137.33 |
Balance Sheet
The company has 18.41 billion in cash and 940.09 million in debt, giving a net cash position of 17.47 billion or 284.10 per share.
Cash & Cash Equivalents | 18.41B |
Total Debt | 940.09M |
Net Cash | 17.47B |
Net Cash Per Share | 284.10 |
Equity (Book Value) | 33.68B |
Book Value Per Share | 547.59 |
Working Capital | 20.84B |
Cash Flow
In the last 12 months, operating cash flow was 7.21 billion and capital expenditures -275.93 million, giving a free cash flow of 6.93 billion.
Operating Cash Flow | 7.21B |
Capital Expenditures | -275.93M |
Free Cash Flow | 6.93B |
FCF Per Share | 112.67 |
Margins
Gross margin is 94.54%, with operating and profit margins of 34.95% and 37.59%.
Gross Margin | 94.54% |
Operating Margin | 34.95% |
Pretax Margin | 42.60% |
Profit Margin | 37.59% |
EBITDA Margin | 36.40% |
EBIT Margin | 34.95% |
FCF Margin | 29.91% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 3.37% |
Shareholder Yield | n/a |
Earnings Yield | 8.92% |
FCF Yield | 7.09% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | |
Lynch Upside | |
Graham Number | |
Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Genmab has an Altman Z-Score of 9.99 and a Piotroski F-Score of 5.
Altman Z-Score | 9.99 |
Piotroski F-Score | 5 |